185 related articles for article (PubMed ID: 35356259)
1. Topical heparin as an effective and safe treatment for patients with capecitabine-induced hand-foot syndrome: results of a phase IIA trial supported by proteomic profiling of skin biopsies.
Rodríguez-Garzotto A; Iglesias-Docampo L; Díaz-García CV; Ruppen I; Ximénez-Embún P; Gómez C; Rodríguez-Peralto JL; de Frutos JO; Lopez-Martin JA; Grávalos C; Cortés-Funes H; Agulló-Ortuño MT
Ther Adv Med Oncol; 2022; 14():17588359221086911. PubMed ID: 35356259
[TBL] [Abstract][Full Text] [Related]
2. Randomized double-blind, placebo-controlled study of topical diclofenac in the prevention of hand-foot syndrome in patients receiving capecitabine (the D-TORCH study).
Santhosh A; Kumar A; Pramanik R; Gogia A; Prasad CP; Gupta I; Gupta N; Cheung WY; Pandey RM; Sharma A; Batra A
Trials; 2022 May; 23(1):420. PubMed ID: 35590388
[TBL] [Abstract][Full Text] [Related]
3. Hand-foot syndrome in cancer patients on capecitabine: examining prevalence, impacts, and associated risk factors at a cancer centre in Malaysia.
King TL; Voon PJ; Yuen KH; Mohamed Noor DA
Support Care Cancer; 2024 May; 32(6):345. PubMed ID: 38743316
[TBL] [Abstract][Full Text] [Related]
4. Mapisal Versus Urea Cream as Prophylaxis for Capecitabine-Associated Hand-Foot Syndrome: A Randomized Phase III Trial of the AIO Quality of Life Working Group.
Hofheinz RD; Gencer D; Schulz H; Stahl M; Hegewisch-Becker S; Loeffler LM; Kronawitter U; Bolz G; Potenberg J; Tauchert F; Al-Batran SE; Schneeweiss A
J Clin Oncol; 2015 Aug; 33(22):2444-9. PubMed ID: 26124485
[TBL] [Abstract][Full Text] [Related]
5. Treatment of capecitabine-induced hand-foot syndrome using a topical retinoid: A case report.
Inokuchi M; Ishikawa S; Furukawa H; Takamura H; Ninomiya I; Kitagawa H; Fushida S; Fujimura T; Ohta T
Oncol Lett; 2014 Feb; 7(2):444-448. PubMed ID: 24396465
[TBL] [Abstract][Full Text] [Related]
6. Topical Silymarin Administration for Prevention of Capecitabine-Induced Hand-Foot Syndrome: A Randomized, Double-Blinded, Placebo-Controlled Clinical Trial.
Elyasi S; Shojaee FSR; Allahyari A; Karimi G
Phytother Res; 2017 Sep; 31(9):1323-1329. PubMed ID: 28635153
[TBL] [Abstract][Full Text] [Related]
7. Hand-foot syndrome induced changes of the palmar epidermal ridge configurations during and after treatment with capecitabine.
Hartung B; Thiel W; Ritz-Timme S; Häussinger D; Erhardt A
Leg Med (Tokyo); 2020 Apr; 45():101710. PubMed ID: 32353749
[TBL] [Abstract][Full Text] [Related]
8. Effect of a Novel Soaking Solution Used in Patients With Hand-Foot Syndrome as a Result of Capecitabine Treatment: A Randomized and Self-Controlled Trial.
Xie Y; Wang Q; Hu T; Chen R; Wang J; Chang H; Peng X; Cheng J
Clin Breast Cancer; 2022 Jul; 22(5):e685-e690. PubMed ID: 35354530
[TBL] [Abstract][Full Text] [Related]
9. Topical non-occlusive polymers in hand-foot syndrome.
Fabbrocini G; Cristaudo A; Ionescu MA; Panariello L; Robert G; Pellicano M; Ayala F
G Ital Dermatol Venereol; 2018 Apr; 153(2):165-171. PubMed ID: 29564873
[TBL] [Abstract][Full Text] [Related]
10. Capecitabine-Induced Genital Hand-Foot Syndrome Treated With Topical Tacrolimus.
Chan BL; Wang T
Cureus; 2024 Apr; 16(4):e57570. PubMed ID: 38707169
[TBL] [Abstract][Full Text] [Related]
11. Randomized trial of vitamin B6 for preventing hand-foot syndrome from capecitabine chemotherapy.
Braik T; Yim B; Evans AT; Kassem M; Mullane M; Lad T; Hussein L; Cleveland B; McDunn S
J Community Support Oncol; 2014 Feb; 12(2):65-70. PubMed ID: 24971407
[TBL] [Abstract][Full Text] [Related]
12. Clinical evidence of prevention strategies for capecitabine-induced hand-foot syndrome.
Huang XZ; Chen Y; Chen WJ; Zhang X; Wu CC; Wang ZN; Wu J
Int J Cancer; 2018 Jun; 142(12):2567-2577. PubMed ID: 29355976
[TBL] [Abstract][Full Text] [Related]
13. The effectiveness of EVOSKIN®Palm and sole moisturizing cream in treating capecitabine-associated hand-foot syndrome: a randomized double-blind clinical trial.
Lu W; Huang Z; Chen S; Lv H; Chen X; Lei J; Ke C; Hong C; Wei Y; Su R; Chen R; Sun Z; Yang P; Tan X; Liu H
Ann Palliat Med; 2021 Mar; 10(3):3009-3017. PubMed ID: 33849091
[TBL] [Abstract][Full Text] [Related]
14. Effect of a Structured Teaching Module Including Intensive Prophylactic Measures on Reducing the Incidence of Capecitabine-Induced Hand-Foot Syndrome: Results of a Prospective Randomized Phase III Study.
Ostwal V; Kapoor A; Mandavkar S; Chavan N; Gupta T; Mirani J; Saklani A; Desouza A; Murugan K; Nashikkar C; Gupta S; Ramaswamy A
Oncologist; 2020 Dec; 25(12):e1886-e1892. PubMed ID: 32717127
[TBL] [Abstract][Full Text] [Related]
15. A randomised controlled feasibility trial to evaluate Lawsonia inermis (henna)'s effect on palmar-plantar erythrodysesthesia induced by capecitabine or pegylated liposomal doxorubicin.
Stavrinou M; Tsitsi T; Astras G; Paikousis L; Charalambous A
Eur J Oncol Nurs; 2021 Apr; 51():101908. PubMed ID: 33626423
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of oral administration of cystine and theanine in colorectal cancer patients undergoing capecitabine-based adjuvant chemotherapy after surgery: a multi-institutional, randomized, double-blinded, placebo-controlled, phase II trial (JORTC-CAM03).
Hamaguchi R; Tsuchiya T; Miyata G; Sato T; Takahashi K; Miura K; Oshio H; Ohori H; Ariyoshi K; Oyamada S; Iwase S
Support Care Cancer; 2020 Aug; 28(8):3649-3657. PubMed ID: 31811480
[TBL] [Abstract][Full Text] [Related]
17. Compliance and effective management of the hand-foot syndrome in colon cancer patients receiving capecitabine as adjuvant chemotherapy.
Son HS; Lee WY; Lee WS; Yun SH; Chun HK
Yonsei Med J; 2009 Dec; 50(6):796-802. PubMed ID: 20046420
[TBL] [Abstract][Full Text] [Related]
18. Analysis of drug-induced hand-foot syndrome using a spontaneous reporting system database.
Yoshida Y; Sasaoka S; Tanaka M; Matsumoto K; Inoue M; Satake R; Shimada K; Mukai R; Suzuki T; Iwata M; Goto F; Mori T; Mori K; Yoshimura T; Nakamura M
Ther Adv Drug Saf; 2022; 13():20420986221101963. PubMed ID: 35646307
[TBL] [Abstract][Full Text] [Related]
19. Hand-Foot Syndrome Presentation Post-Capecitabine Treatment in a Black Patient.
Whorton AE; Razzak AN; Jha P
Cureus; 2022 Jul; 14(7):e26891. PubMed ID: 35978746
[TBL] [Abstract][Full Text] [Related]
20. SNPs in the COX-2/PGES/EP signaling pathway are associated with risk of severe capecitabine-induced hand-foot syndrome.
Liao X; Huang L; Yu Q; He S; Li Q; Huang C; Yuan X
Cancer Chemother Pharmacol; 2020 Apr; 85(4):785-792. PubMed ID: 32193619
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
